Abstract
Overview
Introduction
Despite being the most common cause of death from gynecological tumors,
ovarian cancer has not traditionally attracted the same level of R&D interest
as other female cancers. Nevertheless, nearly 60,000 cases of ovarian cancer
being diagnosed in the seven major markets each year is, by no means, small
and therefore, it remains an important secondary indication for existing and
pipeline drugs.
Scope
- Overview of disease including epidemiology, biology of ovarian cancer,
staging and prognostic factors
- Review of current treatment controversies and physician opinion of
existing and future treatment strategies
- Evaluation of key drug regimens currently used in first, second and third
line for ovarian cancer
- Assessment of late-phase drugs in development for ovarian cancer including
key opinion leaders' view on their potential
Report Highlights
Carboplatin plus paclitaxel remains firmly established as the treatment of
choice not only in first line but also in second line given the significant
proportion of patients retaining platinum sensitivity. It will be difficult
for cytotoxics in development to penetrate the ovarian cancer market unless
product differentiation can be ascertained.
Opinion leaders interviewed by Datamonitor view vascular endothelial growth
factor (VEGF) inhibitors as promising for ovarian cancer. In particular,
Genentech/Roche's Avastin is considered to have the most potential, so much so
that it is believed to be used significantly off-label despite the halting of
a Phase II trial due to safety concerns.
There are nine drugs in Phase II development for ovarian cancer including a
number of cytotoxic and molecular-targeted therapies. Although quite
significant in number, most of the Phase III drugs are being investigated for
ovarian cancer as a secondary indication and are unlikely to make a
significant impact in the disease.
Reasons to Purchase
- Evaluate opportunities and risks in the ovarian cancer market by analyzing
the clinical and commercial attractiveness of key drug regimens
- Understand current and future competitive dynamics of ovarian cancer to
determine the future size and scope of the market
- Assess key success factors that drive the ovarian cancer market to
estimate the potential of existing and pipeline drugs for the disease
| 
View Cart
